On the fractional CMO decision
Why and When Should an AI-Driven Biotech Hire a Fractional CMO?
Published 2026-08-05 · A companion to the fractional CMO engagement and the Calibration Sprint.
An AI-driven biotech is, almost by definition, unbalanced on purpose. The founding team is deep where it matters most early — computation, biology, the model that found the target or ranked the candidate. That imbalance is a feature: it is why the company exists and why it can move faster than an incumbent. But it has a predictable shadow. The judgment that decides whether a promising molecule survives contact with the FDA — endpoint choice, indication, trial design, how the first agency conversation is framed — is usually the last seat the team fills, and often the seat it fills too late.
A full-time Chief Medical Officer is the eventual answer. The question this piece is about is what you do in the eighteen months before you can justify one — when the clinical-regulatory decisions are already in front of you but the company is not yet the size, or the stage, that a full-time CMO requires. That is the gap a fractional CMO exists to close.
What a fractional CMO actually is — and three things it is not
A fractional Chief Medical Officer is a senior physician-executive who owns your clinical and regulatory strategy part-time, on a contract basis, and is accountable for the decisions that come with the title. For an early oncology company that means the person deciding what endpoint you take to the agency, in what indication, in a trial that can actually enroll — is in the room now, rather than after a nine-month executive search, or not at all.
It helps to be precise about what it is not, because three adjacent things get confused with it:
- It is not a consultant. A consultant delivers a document and leaves. A fractional CMO makes decisions and lives with them. If what you need is one analysis — "is this endpoint defensible?" — you do not need a fractional executive; you need a scoped piece of work.
- It is not a name on the deck. An advisor whose contribution is a logo on a slide and a quarterly call is not carrying decision risk. The whole value of the fractional structure is that someone senior is accountable, not merely available.
- It is not a full-time CMO on a discount. A fractional role retires near-term decision risk. It does not build a long-term clinical-regulatory function — the team, the SOPs, the culture — on the calendar required to build one. If what you actually need is that function, the fractional role is a bridge to it, not a substitute for it.
Why the AI-driven biotech in particular
The general case for fractional clinical leadership in biotech is well understood: senior judgment without a senior salary, at a stage where capital is the constraint. The AI-native case is sharper, because the failure modes are specific.
Across AI-oncology programs, the ways a well-funded, technically excellent company hits the FDA wall tend to rhyme. Three recur — I've written about them at length as the Three Ways thesis:
- The endpoint that was never a drug. The model optimizes something — a molecular signature, a response probability — that is not what a review division will adjudicate. The prediction is impressive and the endpoint is unreviewable.
- The patient who was never going to enroll. The trial is designed against an idealized population that does not match referral patterns, line-of-therapy reality, or what community oncologists will actually prescribe. It is pristine on paper and cannot enroll in the clinic.
- The black box that cannot be audited. The model's provenance and validation are real but have never been translated into the language and documentation tier a CDER reviewer will accept.
Notice that none of these is a modeling failure. They are calibration failures — gaps between what the system produces and what the agency requires. And every one of them is exactly the kind of judgment a full-time CMO would normally catch, which is precisely why a company without that seat is exposed to all three at once. The scarce input in an AI-oncology program is not the AI. It is the senior operator who knows when the AI is wrong, and has the FDA interactions to prove it. A fractional CMO is the earliest point at which you can put that judgment on the org chart.
When to hire one — the signals
Hire a fractional CMO when several of these are true at the same time:
- You have a pre-IND or Phase I decision arc immediately in front of you — endpoint, indication, trial design, the first real FDA interaction — and the next eight to twelve decisions are the ones that determine whether the molecule reaches Phase II.
- You have closed a Series A or B in the last 18 months, so there is a program and a clock but not yet the scale that justifies a full-time hire.
- You are translating AI outputs into a regulatory path for the first time, and no one currently on the team has taken a molecule through that translation before.
- Your board is asking clinical-regulatory questions your team cannot answer with confidence — and you are answering them with optimism instead of judgment.
- You are 6 to 18 months from an FDA meeting — close enough that the decisions are real, far enough that there is still time to change the program rather than apologize for it.
The timing principle underneath all of these: the cheapest moment to correct a development program is before the protocol is locked and before the capital is committed. The most expensive moment is inside the pre-IND meeting, when the misalignment surfaces in front of the agency. A fractional CMO is worth most in the window between those two — and that window is earlier than most founders expect.
When not to — the honest anti-signals
Refusal is part of an honest answer. A fractional CMO is the wrong call when:
- You are pre-candidate. If you have a platform and a hypothesis but no lead molecule and no near-term agency interaction, there is no decision of consequence for senior clinical-regulatory judgment to make yet. Spend the money elsewhere and revisit when a candidate and a clock exist.
- You need one document, not an executive. A single defensible answer — "does this surrogate endpoint hold up?" — is a scoped engagement, not a fractional role. Buying the executive to get the document is overpaying.
- You are at pivotal or registration scale. Once the clinical function is large and the filings are continuous, a part-time seat cannot carry the load. You need a full-time CMO, and the fractional role should have been the bridge that got you there.
- You want reassurance, not adjudication. If the real goal is a senior name to validate a decision already made, that is not judgment — it is cover, and it is the one thing a calibrated operator will decline to sell.
The AI-platform variant
If you are not a biotech but an AI-platform company selling into pharma, the CMO-shaped need still exists — it just shows up at a different interface. Your FDA exposure runs through your partners' submissions. The judgment you need is about what regulatory-readiness support you can credibly offer a partner, what must stay partner-owned, and which commercial claims will not survive the partner's own regulatory team. The fractional structure adapts; the question shifts from "will the agency accept our program?" to "can our partner defend our role in theirs?" The platform-shaped first 90 days traces that arc.
How to start without over-committing
A fractional CMO is a genuine commitment on both sides, so it rarely makes sense to start cold. The lower-risk on-ramp is a fixed-scope, two-week Calibration Sprint on a single decision — the one most likely to be miscalibrated — which tells you whether the deeper role is warranted before either side signs up for six to eighteen months. If it is, the engagement converts. If the program turns out to need less than you feared, an honest operator says so. That path — a scoped Sprint first, the fractional seat only where the work earns it — is how OncAdios structures the question, and it is the version I would recommend to a founder weighing the decision even if the answer turns out to be "not yet."
If a clinical-regulatory decision your program cannot afford to get wrong is in front of you in the next 90 to 180 days, that is the signal — and the conversation is worth having.
Jesús Gómez-Navarro, M.D., is a medical oncologist and drug development executive, and founder of OncAdios LLC. He advises AI-oncology and biotech companies as a fractional CMO, board director, or co-founder.